Yunling Du

发表

Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody

M. Krempf, G. Luc, P. Hopkins, 2015, Circulation. Cardiovascular genetics.

Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial.

P. Thompson, E. Steinhagen-Thiessen, K. Parhofer, 2016, Journal of clinical lipidology.

Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials).

J. Mckenney, D. Gaudet, E. Stein, 2014, The American journal of cardiology.

Patient experience in a randomized trial of a weekly progesterone vaginal ring versus a daily progesterone gel for luteal support after in vitro fertilization.

E. Ginsburg, G. Daftary, K. Silverberg, 2018, Fertility and sterility.

Evolution of TCP Phase During Long Term Thermal Exposure in Several Re-Containing Single Crystal Superalloys

Yi-zhou Zhou, Xiao-feng Sun, Jinguo Li, 2019, Acta Metallurgica Sinica (English Letters).

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

G. Yancopoulos, N. Stahl, E. Stein, 2012, The New England journal of medicine.

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial

P. Thompson, E. Steinhagen-Thiessen, M. Cornier, 2016, European heart journal.

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial.

C. Cannon, P. Thompson, E. Bruckert, 2015, Journal of clinical lipidology.

Efficacy and Safety of Alirocumab as Add‐on Therapy in High–Cardiovascular‐Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies

Jennifer G. Robinson, H. Colhoun, H. Bays, 2014, Clinical cardiology.

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.

E. Steinhagen-Thiessen, H. Colhoun, M. Farnier, 2016, Atherosclerosis.

Occurrence and Distribution of Tetrabromobisphenol A and Diversity of Microbial Community Structure in the Sediments of Mangrove

Chongling Yan, Yongcan Jiang, Yunling Du, 2023, Biology.

Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials).

J. Mckenney, D. Gaudet, E. Stein, 2014, The American journal of cardiology.

Abstract 16265: Inhibition of Proprotein Convertase Subtilisin/Kexin Type 9 With a Monoclonal Antibody REGN727/SAR236553, Effectively Reduces Low-Density-Lipoprotein Cholesterol, as Mono or Add-on Therapy in Heterozygous Familial and Non Familial Hypercholesterolemia

E. Stein, S. Mellis, R. Wu, 2011 .